ALNYLAM PHARMACEUTICALS, INC. License and Services Revenue (Deprecated 2018-01-31)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported License and Services Revenue (Deprecated 2018-01-31) of $21.90 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Income Statement › Other Income
us-gaap:LicenseAndServicesRevenue · last filed 2018-05-04
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $21.90M, a 15.50% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $37.92M, a 117.28% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $17.10M, a 25.24% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $15.93M, a 82.94% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2017 was $89.91M, a 90.66% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2016 was $47.16M, a 14.75% increase from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2015 was $41.10M, a 18.72% decline from fiscal 2014.
- ALNYLAM PHARMACEUTICALS, INC. license and services revenue (deprecated 2018-01-31) for fiscal 2014 was $50.56M, a 7.20% increase from fiscal 2013.
| Period end | License and Services Revenue (Deprecated 2018-01-31) 3 month | License and Services Revenue (Deprecated 2018-01-31) 6 month | License and Services Revenue (Deprecated 2018-01-31) 9 month | License and Services Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $21.90M 10-Q · filed 2018-05-04 | $59.82M derived: sum of 2 quarters · filed 2018-05-04 | $76.92M derived: sum of 3 quarters · filed 2018-05-04 | $92.85M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-12-31 | $37.92M 10-K · filed 2018-02-15 | $55.02M derived: sum of 2 quarters · filed 2018-02-15 | $70.95M derived: sum of 3 quarters · filed 2018-02-15 | $89.91M 10-K · filed 2018-02-15 |
| 2017-09-30 | $17.10M 10-K · filed 2018-02-15 | $33.03M derived: sum of 2 quarters · filed 2018-02-15 | $51.99M 10-Q · filed 2017-11-07 | $69.44M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-06-30 | $15.93M 10-K · filed 2018-02-15 | $34.89M 10-Q · filed 2017-08-09 | $52.35M derived: sum of 3 quarters · filed 2018-05-04 | $66.00M derived: sum of 4 quarters · filed 2018-05-04 |
| 2017-03-31 | $18.96M 10-Q · filed 2018-05-04 | $36.41M derived: sum of 2 quarters · filed 2018-05-04 | $50.06M derived: sum of 3 quarters · filed 2018-05-04 | $58.77M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | $17.45M 10-K · filed 2018-02-15 | $31.11M derived: sum of 2 quarters · filed 2018-02-15 | $39.81M derived: sum of 3 quarters · filed 2018-02-15 | $47.16M 10-K · filed 2018-02-15 |
| 2016-09-30 | $13.65M 10-K · filed 2018-02-15 | $22.36M derived: sum of 2 quarters · filed 2018-02-15 | $29.70M 10-Q · filed 2017-11-07 | $37.26M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $8.71M 10-K · filed 2018-02-15 | $16.05M 10-Q · filed 2017-08-09 | $23.61M derived: sum of 3 quarters · filed 2018-02-15 | $29.93M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $7.34M 10-K · filed 2018-02-15 | $14.90M derived: sum of 2 quarters · filed 2018-02-15 | $21.22M derived: sum of 3 quarters · filed 2018-02-15 | $29.91M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $7.55M 10-K · filed 2017-02-15 | $13.88M derived: sum of 2 quarters · filed 2017-02-15 | $22.56M derived: sum of 3 quarters · filed 2017-02-15 | $41.10M 10-K · filed 2018-02-15 |
| 2015-09-30 | $6.32M 10-K · filed 2017-02-15 | $15.01M derived: sum of 2 quarters · filed 2017-02-15 | $33.55M 10-Q · filed 2016-11-03 | $57.56M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $8.69M 10-K · filed 2017-02-15 | $27.22M 10-Q · filed 2016-08-04 | $51.24M derived: sum of 3 quarters · filed 2017-02-15 | $62.21M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $18.54M 10-K · filed 2017-02-15 | $42.56M derived: sum of 2 quarters · filed 2017-02-15 | $53.53M derived: sum of 3 quarters · filed 2017-02-15 | $60.82M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $24.02M 10-K · filed 2016-02-12 | $34.99M derived: sum of 2 quarters · filed 2016-02-12 | $42.29M derived: sum of 3 quarters · filed 2016-02-12 | $50.56M 10-K · filed 2017-02-15 |
| 2014-09-30 | $10.97M 10-K · filed 2016-02-12 | $18.27M derived: sum of 2 quarters · filed 2016-02-12 | $26.54M 10-Q · filed 2015-11-09 | $37.39M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $7.29M 10-K · filed 2016-02-12 | $15.57M 10-Q · filed 2015-08-07 | $26.42M derived: sum of 3 quarters · filed 2016-02-12 | $35.41M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $8.28M 10-K · filed 2016-02-12 | $19.12M derived: sum of 2 quarters · filed 2016-02-12 | $28.11M derived: sum of 3 quarters · filed 2016-02-12 | $36.80M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $10.85M 10-K · filed 2015-02-13 | $19.84M derived: sum of 2 quarters · filed 2015-02-13 | $28.52M derived: sum of 3 quarters · filed 2015-02-13 | $47.17M 10-K · filed 2016-02-12 |
| 2013-09-30 | $8.99M 10-K · filed 2015-02-13 | $17.68M derived: sum of 2 quarters · filed 2015-02-13 | $36.32M 10-Q · filed 2014-11-06 | $44.81M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $8.69M 10-K · filed 2015-02-13 | $27.33M 10-Q · filed 2014-08-08 | $35.82M derived: sum of 3 quarters · filed 2015-02-13 | $52.58M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $18.64M 10-K · filed 2015-02-13 | $27.14M derived: sum of 2 quarters · filed 2015-02-13 | $43.90M derived: sum of 3 quarters · filed 2015-02-13 | $64.78M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $8.49M 10-K · filed 2014-02-20 | $25.25M derived: sum of 2 quarters · filed 2014-02-20 | $46.14M derived: sum of 3 quarters · filed 2014-02-20 | $66.72M 10-K · filed 2015-02-13 |
| 2012-09-30 | $16.76M 10-K · filed 2014-02-20 | $37.64M derived: sum of 2 quarters · filed 2014-02-20 | $58.23M 10-Q · filed 2013-11-07 | $78.69M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | $20.88M 10-K · filed 2014-02-20 | $41.47M 10-Q · filed 2013-08-09 | $61.93M derived: sum of 3 quarters · filed 2014-02-20 | $82.72M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | $20.59M 10-K · filed 2014-02-20 | $41.04M derived: sum of 2 quarters · filed 2014-02-20 | $61.83M derived: sum of 3 quarters · filed 2014-02-20 | $82.45M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | $20.45M 10-K · filed 2013-02-19 | $41.25M derived: sum of 2 quarters · filed 2013-02-19 | $61.86M derived: sum of 3 quarters · filed 2013-02-19 | $82.76M 10-K · filed 2014-02-20 |
| 2011-09-30 | $20.79M 10-K · filed 2013-02-19 | $41.41M derived: sum of 2 quarters · filed 2013-02-19 | $62.30M 10-Q · filed 2012-11-05 | $83.49M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | $20.61M 10-K · filed 2013-02-19 | $41.51M 10-Q · filed 2012-08-08 | $62.70M derived: sum of 3 quarters · filed 2013-02-19 | $90.37M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $20.90M 10-K · filed 2013-02-19 | $42.09M derived: sum of 2 quarters · filed 2013-02-19 | $69.76M derived: sum of 3 quarters · filed 2013-02-19 | $96.37M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $48.86M derived: sum of 2 quarters · filed 2013-02-19 | $75.48M derived: sum of 3 quarters · filed 2013-02-19 | $100.04M 10-K · filed 2013-02-19 |
| 2010-09-30 | $27.67M 10-Q · filed 2011-11-03 | $54.28M derived: sum of 2 quarters · filed 2011-11-03 | $78.85M 10-Q · filed 2011-11-03 | |
| 2010-06-30 | $26.62M 10-Q · filed 2011-08-03 | $51.18M 10-Q · filed 2011-08-03 | ||
| 2009-12-31 | $100.53M 10-K · filed 2012-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |